Response to Chadi A. Calarge re: "Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)"
J Child Adolesc Psychopharmacol
.
2024 Mar;34(2):104-105.
doi: 10.1089/cap.2023.0085.
Epub 2024 Feb 13.
Authors
Francesca Kolitsopoulos
1
,
Sara Ramaker
2
,
Philip Chappell
3
,
Samuel Broderick
4
,
Warren Bao
5
,
Yuliya Lokhnygina
4
,
Scott Compton
6
,
John Orazem
2
3
Affiliations
1
Global Medical Epidemiology, Pfizer, New York, New York, USA.
2
Global Product Development, Pfizer, Collegeville, Pennsylvania, USA.
3
Global Product Development, Pfizer, Groton, Connecticut, USA.
4
Department of Statistics, Duke Clinical Research Institute, Durham, North Carolina, USA.
5
Global Product Development, Pfizer, New York, New York, USA.
6
Department of Psychiatry, Duke University School of Medicine, Durham, North Carolina, USA.
PMID:
38350152
DOI:
10.1089/cap.2023.0085
No abstract available
Publication types
Letter
Comment
MeSH terms
Child
Humans
Selective Serotonin Reuptake Inhibitors* / adverse effects
Sertraline* / adverse effects
Substances
Sertraline
Selective Serotonin Reuptake Inhibitors